Literature DB >> 30251220

The Use of Serum MMP-9 and TIMP-1 in Acute Coronary Syndrome.

Laura Lahdentausta1,2, Timo Sorsa3,4,5, Erkki Pesonen6,7, Pirkko Pussinen3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30251220     DOI： 10.1007/s12265-018-9833-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN： 1937-5387            Impact factor:   4.132


× No keyword cloud information.
  5 in total

1.  Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood.

Authors:  Caroline Alby; Ouardia Ben Abdesselam; Marie-José Foglietti; Jean-Louis Beaudeux
Journal:  Clin Chim Acta       Date:  2002-11       Impact factor: 3.786

2.  Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.

Authors:  Raquel F Gerlach; Juliana A Uzuelli; Caroline D Souza-Tarla; Jose E Tanus-Santos
Journal:  Anal Biochem       Date:  2005-09-01       Impact factor: 3.365

3.  Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.

Authors:  K Jung; C Laube; M Lein; R Lichtinghagen; H Tschesche; D Schnorr; S A Loening
Journal:  Clin Chem       Date:  1998-05       Impact factor: 8.327

4.  Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases.

Authors:  Indiara V Santana; Jose E Tanus-Santos
Journal:  J Cardiovasc Transl Res       Date:  2018-08-21       Impact factor: 4.132

5.  Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence.

Authors:  Laura Lahdentausta; Jaakko Leskelä; Alina Winkelmann; Taina Tervahartiala; Timo Sorsa; Erkki Pesonen; Pirkko J Pussinen
Journal:  J Cardiovasc Transl Res       Date:  2018-01-18       Impact factor: 4.132
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.